^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

222-K Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)

Published date:
11/04/2023
Excerpt:
We then stratified the 36 HNSCC patients treated with nivolumab into the same G1-G5 immunotypes as a validation cohort. At baseline, the G2 group had higher OR rates than other groups (p=0.02; figure 2). Baseline primary tumors showed OR correlated with PD-L1 and PD-L2 expression, interferon responsive genes, T-cell trafficking, and MHC class I pathway (higher values in Responders versus Non-responders, p<0.05; figure 3).
DOI:
10.1136/jitc-2023-SITC2023.0222-K
Trial ID: